Skip to main
VNRX

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX is a biotechnology company with a strong focus on developing simple and cost-effective blood tests for the diagnosis and monitoring of diseases associated with NETosis. The recent publication of a peer-reviewed clinical study conducted with the Mayo Clinic provides additional validation for the company's Nu.Q platform, particularly in acute care settings. While this is a positive development, the company still faces risks in terms of clinical adoption, regulatory clarity, and integration into clinical workflows before it can generate meaningful revenue.

Bears say

VolitionRX is facing multiple negative factors, including a recent reverse stock split that raises concerns about financial stress and business strength. In addition, the company's ongoing focus on capital structure and exchange compliance may overshadow any clinical progress, making it difficult for the stock to gain positive momentum. Furthermore, the company may need to raise additional capital to fund operations beyond mid-2026, which could further dampen investor confidence.

Volitionrx Limited (VNRX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.